Characterization and diagnostic potential of hepatitis B virus nucleocapsid expressed in E. coli and P. pastoris

Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery

Virus-like particles (VLPs) are empty, nanoscale structures morphologically resembling viruses. Internal cavity, noninfectious, and particulate nature with a high density of repeating epitopes, make them an ideal platform for vaccine development and drug delivery. Commercial use of Gardasil-9 and Cervarix showed the usefulness of VLPs in vaccine formulation. Further, chimeric VLPs allow the raising of an immune response against different immunogens and thereby can help reduce the generation of medical or clinical waste. The economically viable production of VLPs significantly impacts their usage, application, and availability. To this end, several hosts have been used and tested. The present review will discuss VLPs produced using different yeasts as fermentation hosts. We also compile a list of studies highlighting the expression and purification of VLPs using a yeast-based platform. We also discuss the advantages of using yeast to generate VLPs over other available systems. Further, the issues or limitations of yeasts for producing VLPs are also summarized. The review also compiles a list of yeast-derived VLP-based vaccines that are presently in public use or in different phases of clinical trials.

High-level production of recombinant HBcAg virus-like particles in a mathematically modelled P. pastoris GS115 Mut+ bioreactor process under controlled residual methanol concentration

Recombinant hepatitis B core antigen (HBcAg) molecules, produced in heterologous expression systems, self-assemble into highly homogenous and non-infectious virus-like particles (VLPs) that are under extensive research for biomedical applications. HBcAg production in the methylotrophic yeast P. pastoris has been well documented; however, productivity screening under various residual methanol levels has not been reported for bioreactor processes. HBcAg production under various excess methanol levels of 0.1, 1.0 and 2.0 g L⁻¹ was investigated in this research. Results indicate that, under these particular conditions, the total process and specific protein yields of 876–1308 mg L⁻¹ and 7.9–11.2 mg g_DCW⁻¹, respectively, were achieved after 67–75 h of cultivation. Produced HBcAg molecules were efficiently purified and the presence of highly immunogenic, correctly formed and homogenous HBcAg-VLPs with an estimated purity of 90% was confirmed by electron microscopy. The highest reported HBcAg yield of 1308 mg L⁻¹ and 11.2 mg g_DCW⁻¹ was achieved under limiting residual methanol concentration, which is about 2.5 times higher than the next highest reported result. A PI-algorithm-based residual methanol concentration feed rate controller was employed to maintain a set residual methanol concentration. Finally, mathematical process models to characterise the vegetative, dead and total cell biomass (X_v, X_d and X), substrate (Glycerol and Methanol) concentration, reactor volume (V), and product (HBcAg) dynamics during cultivation, were identified. A rare attempt to model the residual methanol concentration during induction is also presented.

Phage displayed HBV core antigen with immunogenic activity

Hepatitis B is a major public health problem worldwide, which may lead to chronic liver diseases such as cirrhosis and hepatocellular carcinoma. The hepatitis B core antigen (HBcAg) is one of the major viral proteins, which forms the inner core of hepatitis B virus (HBV) particles. In this study, filamentous bacteriophage M13 was genetically modified to display the polypeptides of HBcAg in order to develop an alternative carrier system. HBcAg gene was inserted into the minor coat protein (pIII) gene of M13, and HBcAg was expressed on the phage surface as a whole protein. Antigenicity and immunogenicity of HBcAg were tested by immunizing BALB/c mice three times with HBcAg-displaying recombinant phages. After successful immunization, one of the mice with high antibody titer to HBcAg was selected for fusion, and four monoclonal antibodies specific for HBcAg were developed. This result showed that HBcAg-displaying recombinant bacteriophages are immunogenic and can potentially be used for the development of monoclonal antibodies.

CLONAGEM E EXPRESSÃO DO GENE DA GLICOPROTEÍNA S1 DO VÍRUS DA BRONQUITE INFECCIOSA DAS GALINHAS EM PICHIA PASTORIS

RESUMO Variações genética e antigênica são observadas com frequência elevada entre estirpes do VBIG e envolvem principalmente a glicoproteína S1. Com o objetivo de contribuir com a disponibilidade de ferramentas para o imunodiagnóstico e a imunoprofilaxia da bronquite infecciosa das galinhas foi desenvolvida uma metodologia para expressão recombinante da glicoproteína S1 na levedura Picchia pastoris. O cDNA do gene codificador dessa proteína foi obtido a partir de RNA viral de ovos embrionados infectados com a estirpe M41 do VBIG submetido à transcrição reversa (RT) e reação em cadeia da polimerase (PCR), amplificando-se a sequência codificadora de S1 acrescida de extremidades compatíveis com a clonagem no vetor usado na transformação de leveduras. A indução com metanol resultou na produção de uma proteína detectada como banda única do tamanho previsto, em western-blot, no lisado celular das leveduras transformadas. A expressão em P. pastoris mostrou ser um método eficaz para a produção recombinante da proteína S1 do VBIG, com potencial para utilização em técnicas de imunodiagnóstico da bronquite infecciosa das galinhas.

Diagnosis of human hepatitis B virus in non-treated blood by the bovine IgG DNA-linked carbon nanotube biosensor

OBJECTIVES

To identify an effective bioassay for human hepatitis B virus (HBV) using voltammetric sensor.

STUDY DESIGN

Electrode was prepared with bovine IgG immobilized onto a DNA-linked carbon nanotube electrode (BIDCE). Analytical BIDCE conditions were optimized through square wave (SW) stripping and cyclic voltammetry (CV).

RESULTS

Optimum parameters of 75 Hz SW frequency, 0.1 V SW amplitude, -1.3 V SW accumulation potential, 100 s accumulation time, and 3.0 mV SW increment potential were obtained. Within working ranges of 0.035-0.242 mg/mL anti-bovine IgG, the relative standard deviation of 0.2 mL HBV was observed to be 0.04 (n=4).

CONCLUSIONS

Diagnostic application was performed through direct assay of HBV in non-treated human blood.

Secreted expression of the classical swine fever virus glycoprotein Erns in yeast and application to a sandwich blocking ELISA

E(rns) is an envelope glycoprotein of classical swine fever virus (CSFV) with RNase activity. The purpose of this study was to produce an active E(rns) for further applications using the yeast secreted expression system. The E(rns) gene was cloned into the expression vector pGAPZalphaC which was introduced into Pichia pastoris. Expression of E(rns) protein in culture supernatant was confirmed by Western blot analysis using both the monoclonal antibody against CSFV E(rns) and CSFV-positive swine serum. The yeast-expressed E(rns) (yE(rns)) was shown to have N-linked glycosylation and to form homodimer of 74 kDa molecules. All monomer, homodimer, and deglycosylated forms of yE(rns) demonstrated intrinsic ribonuclease activity and a clear preference for uridine-rich sequence. A direct sandwich blocking enzyme-linked immunosorbent assay (ELISA) based on the yE(rns) was developed with a high sensitivity and specificity. The yE(rns) which possesses enzymatic activity and retains antigenicity may provide a useful material for developing a diagnostic kit.

Expression of pseudorabies virus gE epitopes in Pichia pastoris and its utilization in an indirect PRV gE-ELISA

Pseudorabies virus glycoprotein E (PRV gE) has been recognized as a suitable diagnostic antigen for pseudorabies. In order to produce gE antigen in large quantities and at low cost, a gene fragment encoding PRV gE epitopes was expressed in Pichia pastoris expression system. SDS-PAGE and Western blotting revealed that the expression product was two recombinant proteins, approximately 38 and 32 kDa, in the culture supernatant of P. pastoris integrant 72 h after induction. Protein concentration assay showed the expression product amounted to 106.7 mg/l, accounting for 66.67% of total culture supernatant proteins. An indirect PRV gE-ELISA was then established by using the recombinant expression product as a coating antigen. Cross-reactivity assay showed that this antigen was PRV specific. Reproducibility experiment displayed good consistency. Comparison of detection results of 348 field serum samples between PRV gE-ELISA and a commercially available PRV diagnostic kit showed there was no significant difference between these two methods (P > 0.05).